Strengthening the Health Data and Overseas Businesses through a Capital and Business Alliance with OMRON
First written in FY2022. 5 of 8 entries say "Advanced", first in FY2023-Q2. Latest entry: 2026-06-30.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「(1) Areas of business collaboration under this capital and business alliance: ① Strengthening the health-data platform ② Developing preventive solutions ③ Accelerating the overseas expansion of our group ④ Cross-selling devices and services ⑤ Developing and socially implementing OMRON Group's data solutions business」
The company reiterated the collaboration areas under the capital and business alliance with OMRON: health data, prevention, overseas expansion, cross-selling and data solutions. - FY2024-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 8 September 2023, we entered into an amendment agreement to the capital and business alliance agreement with OMRON Corporation (hereinafter, “OMRON”). (1) Development and social implementation of OMRON Group's data solutions business; establishment and promotion of collaboration themes in the areas of industrial automation and social solutions; and the dispatch of personnel from the JMDC Group to OMRON Group and outsourcing of services by OMRON Group to the JMDC Group」
The company entered into an amendment agreement to the capital and business alliance agreement, adding development and social implementation of OMRON Group's data solutions business, collaboration in industrial automation and social solutions, personnel dispatch and outsourcing to the scope of the collaboration. - FY2023-Q3RestatedAnnual report
「Through a public offering of new shares outside Japan, with 20 September 2022 as the payment date, and a third-party allotment of new shares to OMRON Corporation, we issued 5,500,000 new shares. Capital stock and capital surplus each increased by ¥14,732 million and ¥14,558 million, respectively.」
The company reiterated the issuance of 5,500,000 new shares through an overseas offering and a third-party allotment to OMRON, together with the resulting increases in capital. No new changes were disclosed in the capital component of the capital and business alliance. - FY2023-Q2AdvancedAnnual report
「Through a public offering of new shares outside Japan, with 20 September 2022 as the payment date, and a third-party allotment of new shares to OMRON Corporation, we issued 5,500,000 new shares. Capital stock and capital reserves each increased by ¥14,732 million and ¥14,729 million, respectively.」
The company issued new shares, including through a third-party allotment to OMRON, and OMRON held 32.60% of the issued shares as of 30 September 2022. The capital component of the capital and business alliance was put into concrete form. - FY2022First statedAnnual report
「We entered into a capital and business alliance agreement with OMRON Corporation, with the aim of strengthening the health-data platform, developing preventive solutions, accelerating the overseas expansion of our group, and pursuing cross-selling of devices and services.」
In February 2022, OMRON acquired 33.0% of the issued shares, launching an alliance to jointly advance the health-data platform, preventive solutions, overseas expansion and cross-selling of devices and services.